McKesson (MCK) Q1 2027 earnings review
Strong Adjusted Earnings Obscure GAAP Weakness and Segment Divergence
McKesson delivered a powerful headline performance for Q1 FY27, with consolidated revenues growing 8% to $105.4B and Adjusted EPS surging 20% to $9.93. The foundational distribution and oncology businesses continue to print exceptional growth. However, a deeper look reveals a diverging narrative: GAAP Net Income reversed, falling 22%, driven by a massive $293M redemption value adjustment linked to the Apollo minority investment in the Medical-Surgical segment. Furthermore, while the company raised its full-year Adjusted EPS guidance, the Medical-Surgical segment—which McKesson is preparing to spin off—experienced a 20% collapse in Adjusted Operating Profit despite positive top-line growth.
🐂 Bull Case
The Oncology & Multispecialty segment is an unstoppable growth engine, delivering 33% revenue growth and a staggering 41% increase in Adjusted Operating Profit, proving the success of recent network expansions and acquisitions.
McKesson executed a massive $2.5 billion in share repurchases in Q1 alone (largely through a $2.25B ASR) and raised its dividend by 15%, providing a massive structural tailwind to EPS.
🐻 Bear Case
Ahead of its planned spin-off, the Medical-Surgical (Wellverse) segment is showing severe margin compression, with Adjusted Operating Profit reversing to a 20% decline due to unfavorable product mix and administrative expenses.
Working capital bloat—specifically $2.37B tied up in receivables and $2.07B in inventory builds—drove Q1 Free Cash Flow into negative territory at -$372 million.
⚖️ Verdict: ⚪
Cautiously Bullish. The core pharmaceutical and oncology businesses are phenomenally strong, and capital allocation is highly accretive. However, the drastic underperformance of the Medical-Surgical unit right before its planned separation introduces significant structural risk.
Key Themes
Oncology & Multispecialty Platform Accelerating
The strategic pivot to focus heavily on the Oncology & Multispecialty segment is yielding massive dividends. Segment revenues accelerated 33% YoY to $14.2 billion, while Adjusted Segment Operating Profit surged 41% to $405 million. The company cited robust growth in provider solutions and specialty distribution, successfully integrating and scaling recent acquisitions (like PRISM and Core Ventures) to compound its scale advantage.
Medical-Surgical (Wellverse) Margin Collapse Contradicts Spin-Off Optimism
Despite management celebrating progress on the planned separation of the Medical-Surgical business—including securing a $1.25B investment from Apollo Funds and unveiling the 'Wellverse' name—the segment's fundamentals are reversing. While revenue was stable at +4% YoY, Adjusted Segment Operating Profit plummeted 20% to $195 million. Management blamed 'product mix and one-time administrative expenses,' but this margin compression is a glaring red flag for an entity preparing to stand alone.
Working Capital Drag Reversing Cash Flow
McKesson burned through cash in Q1, with Free Cash Flow reversing to -$372 million (compared to -$1.1B in the prior year's Q1, but still a negative print). The cash flow statement shows severe working capital demands: a $2.37B increase in receivables and a $2.07B buildup in inventories. While Q1 is historically a softer cash flow quarter for the company, this magnitude of working capital consumption requires monitoring as it limits dry powder for future M&A.
Financial Engineering via Aggressive Share Repurchases
A significant portion of McKesson's 20% Adjusted EPS growth is subsidized by a shrinking share count. The company returned $2.6 billion to shareholders in Q1, anchored by a $2.25 billion accelerated share repurchase (ASR) program. Diluted weighted-average shares outstanding dropped 5% YoY to 119.2 million. This lever will remain a powerful, stable EPS driver as the company deploys the $1.25 billion in proceeds from the Apollo Medical-Surgical transaction.
RxTS Continues to Capitalize on Biopharma Complexity
The Prescription Technology Solutions (RxTS) segment remains a high-margin growth engine, with Adjusted Operating Profit increasing 13% to $303 million on just 9% revenue growth. This accelerating leverage is driven by biopharma's increasing reliance on McKesson's technology platforms for patient access solutions, particularly in navigating prior authorizations and affordability programs for high-demand, complex therapies.
GAAP vs. Non-GAAP Disconnect
The gap between McKesson's adjusted and reported earnings is widening. Q1 GAAP Net Income fell 22% to $614 million, heavily impacted by a $293 million adjustment to redemption values for redeemable non-controlling interests related to the Apollo Med-Surg deal, plus $136 million in restructuring and impairment charges. While management adjusts these out to show 14% Adjusted Earnings growth, the sheer volume of 'one-time' transaction and restructuring expenses limits the actual cash generation of the business.
Other KPIs
Accelerating. The foundational segment grew Adjusted Operating Profit by 19% YoY, vastly outpacing its 5% revenue growth. This underscores strong operating leverage and a highly favorable product mix, driven heavily by specialty pharmaceutical distribution to health systems and the timing of new product launches.
Stable and compounding. GAAP gross profit increased 12% YoY, proving that despite pricing pressures in branded pharmaceuticals, the shift toward specialty distribution and oncology is structurally improving the company's margin profile.
Guidance
Accelerating. Management raised the full-year guidance range from the previous $43.80–$44.60. The new midpoint ($44.60) implies roughly 14% YoY growth compared to FY26. This raise so early in the fiscal year signals immense confidence in the core distribution and oncology businesses, alongside the accretive math of the $2.25B Q1 accelerated share repurchase.
Key Questions
Medical-Surgical Margin Mechanics
Adjusted Operating Profit for the Medical-Surgical segment declined 20% despite 4% revenue growth. Could you quantify the split between 'product mix' headwinds and the 'one-time administrative expenses'? How quickly will these one-time expenses roll off ahead of the Wellverse spin-off?
Apollo Minority Stake Impact
With Apollo now holding a ~13% stake in the Medical-Surgical business, how will this structure impact the cash flow profile of the segment leading up to the complete separation, and does this change the timeline for the eventual IPO?
Working Capital Normalization
Q1 saw significant cash usage tied to a $2.37B increase in receivables and a $2.07B inventory build. Given the robust 19% operating profit growth in NA Pharma, how much of this working capital drag was seasonal versus structural investments in specialty/cold-chain inventory?